Whether Ozempic is appropriate while breastfeeding depends first on the formulation and then on the mother's clinical needs and the infant's circumstances. The current Ozempic tablet label advises against breastfeeding during treatment because of the absorption enhancer SNAC. The injection label calls for weighing breastfeeding benefits, the mother's clinical need, and possible infant effects. A small study of injected semaglutide provides useful milk-transfer data, but it does not prove safety for every breastfeeding family. Tablet label, section 8.2; injection label, section 8.2
Before starting, stopping, or changing a medicine, have the prescriber and the baby's clinician review the exact product, why it is needed, the baby's age and feeding pattern, and the available alternatives.
Injection and tablet labels answer different questions
| Product | What the source says about lactation | What it does not establish |
|---|---|---|
| Ozempic injection | The label states that human milk, infant-effect, and milk-production data are unavailable and directs an individualized benefit–risk assessment | A blanket statement that injection is safe, or that no human research exists outside the label |
| Ozempic tablets | The label reports semaglutide below quantification in a clinical milk study, but SNAC or its metabolites in milk; breastfeeding is not recommended during treatment | Permission to apply injection research to the tablet |
| Injected semaglutide in a small 2024 study | Semaglutide was not detected in sampled milk from eight women | Proof of zero exposure, newborn safety, normal milk supply, or long-term infant safety |
Sources: injection label, tablet label, and Diab and colleagues, Nutrients 2024.
The difference between a label and a published study is important. A label's statement that data are unavailable should be reported accurately as the label's wording. It should not erase later or separately published research. Equally, one small publication should not be presented as a new blanket approval for lactation.
What did the injectable semaglutide study actually measure?
The 2024 study in *Nutrients* analyzed milk from eight women using injected semaglutide. The reported collection times were 0, 12, and 24 hours after administration. The assay's detection limit was 1.7 ng/mL, and semaglutide was not detected in the samples. The authors also modeled possible infant exposure using the assay's quantification limit; modeled estimates are not measured drug levels in babies. Full study, methods and results
The study examined a limited dose range. The infant-age categories in the study's table ranged from 4–6 months to 12–23 months, and feeding included breast milk with complementary foods or other feeds. The discussion instead describes infants aged 7–23 months, an internal inconsistency that limits precise age-specific conclusions. This was not a study of exclusively breastfed newborns or early colostrum production. One participant reported a compounded preparation, which also limits treating the cohort as a trial of one standardized branded product. Study Tables 1–2
Maternal reports generally described expected growth and development during a short exposure period. One mother reported transient infant diarrhea and decreased appetite; a causal connection could not be established. It would be inaccurate to summarize the study as “no infant symptoms” or “proven harmless.” Study results and discussion
The finding is useful evidence about measured milk transfer under these conditions. The limitations are equally useful: eight participants, limited sampling, early dose titration, maternal reports, and no long-term safety assessment. The study did not measure milk production or milk composition.
Why does the pill have different advice?
Oral semaglutide products use SNAC to support absorption. The current combined Rybelsus and Ozempic tablet label reports SNAC or its metabolites in human milk. It explains that infants may clear SNAC less effectively than adults and that potential accumulation raises concern for serious adverse reactions. For that reason, the label advises that breastfeeding is not recommended during tablet treatment. Tablet label, section 8.2
That statement is formulation-specific. A study of injected semaglutide cannot answer the SNAC question, and finding little or no measurable semaglutide in milk does not resolve risk from another ingredient. If the prescription or packaging is unclear, ask the pharmacist to identify the product before making a feeding or medication decision.
Milk supply and maternal nutrition remain separate concerns
Low measured drug transfer does not tell us whether treatment affects milk quantity or nutritional composition. The study did not measure either. Its authors identified maternal nutrient intake, milk composition, and longer-term infant outcomes as unanswered questions. Appetite reduction and gastrointestinal effects make the mother's ability to eat and drink adequately a relevant part of follow-up, rather than evidence that milk supply will definitely fall. Study discussion and limitations
A clinician should consider the reason for treatment as well as the uncertainty. Managing type 2 diabetes and seeking postpartum weight loss are not identical clinical situations. Neither the need for treatment nor the benefits of breastfeeding should be dismissed with an automatic internet rule.
A shared decision worksheet for your appointment
Bring a medication list and the product packaging, then work through these questions:
| Topic | Details to review together |
|---|---|
| Exact medicine | Injection or tablet, brand, dose, other ingredients, and any compounded preparation |
| Mother's treatment need | The condition being treated, its current control, and suitable alternatives |
| Infant circumstances | Age, prematurity or health concerns, breast-milk intake, feeding pattern, and growth |
| Evidence fit | Whether the available study resembles this mother–infant situation and what remains unknown |
| Follow-up | Who checks maternal intake and symptoms, infant feeding and growth, and when the plan is reassessed |
This worksheet is a discussion aid, not a clearance checklist. The presence of an older infant or mixed feeding does not automatically make a medicine appropriate. If the baby is feeding poorly, has persistent gastrointestinal symptoms, or has growth concerns, contact the baby's clinician promptly.
Related reading: semaglutide side-effects guide.
Educational information only. This article does not replace an individual medication or feeding decision with your care team. Sources checked October 23, 2026.
Frequently Asked Questions
Does “not detected in milk” mean no semaglutide reaches the baby?
No. It means the study did not detect semaglutide above its assay threshold in the collected samples. It does not prove zero drug transfer or measure all possible infant exposure over a weekly dosing interval.
Can I pump and discard milk for 24 hours after an injection?
The study's 0-, 12-, and 24-hour collection schedule was a research design, not a validated “pump and discard” protocol. It does not establish a safe waiting interval. Ask your clinicians for a product-specific plan rather than deriving one from those sampling times.
Is the Ozempic pill treated the same as the injection during breastfeeding?
No. The current tablet label advises against breastfeeding during treatment because of SNAC-related concerns. Injection research should not override that advice.
Should I stop a medicine or stop breastfeeding after reading this?
This article cannot decide that for an individual family. Contact the prescriber and the baby's clinician to review the exact formulation and clinical situation. For related reading, see our semaglutide side-effects guide; pregnancy and lactation require their own discussions.
Sources
This article is based on the following primary sources. Links open the original documents.
- 1.Ozempic injection prescribing information, section 8.2 Lactation · DailyMed, U.S. National Library of Medicine · accessed
- 2.Rybelsus and Ozempic tablets prescribing information, section 8.2 Lactation · DailyMed, U.S. National Library of Medicine · accessed
- 3.Subcutaneous Semaglutide during Breastfeeding: Infant Safety Regarding Drug Transfer into Human Milk · Diab and colleagues, Nutrients 2024 · accessed
Telehealth prescribing rules differ by state. Read the state-by-state guide.
Majesta Health articles are written against primary sources (FDA labeling, NIH and CDC publications, state statutes) and each one passes a documented compliance review before publication. Where an article cites external sources, they are listed at the end of that article so you can check them yourself. No article currently carries an individual physician review; when a physician reviews an article, that page will show the reviewer's name, NPI and review date.
- Written against primary sources: FDA labeling and safety communications, NIH and CDC publications, state statutes and medical board rules
- Documented compliance review against FDA, FTC and LegitScript requirements before publication
- External sources, where an article cites them, are listed at the end of that article with links to the original documents
- Compounded medications are described as not FDA-approved as final products on every page that mentions them